NCT03472014View on ClinicalTrials.gov

Special Access Program IMVAMUNE®

PHASE4CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

April 22, 2010

Primary Completion Date

November 14, 2014

Study Completion Date

November 14, 2014

Conditions

Vaccination

Interventions

BIOLOGICAL

IMVAMUNE®

IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose

Trial Locations (1)

94301

Palo Alto Medical Foundation, Palo Alto

Sponsors

Lead Sponsor

Bavarian Nordic

All Listed Sponsors

lead

Bavarian Nordic

INDUSTRY